{"log_id": 8175665243864874722, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 1.1e-05, "average": 0.997702, "min": 0.986308}, "location": {"width": 808, "top": 179, "height": 27, "left": 212}, "words": "者的生活质量较基线有了明显的改善(应用鼻炎结膜炎生活质量调查问卷(RQLQ)评价)"}, {"probability": {"variance": 0.006866, "average": 0.975229, "min": 0.480616}, "location": {"width": 781, "top": 211, "height": 28, "left": 222}, "words": "(所有试验中最小显著差异=较安慰剂至少改善一0.5;治疗差异为-0.690,P<0.001"}, {"probability": {"variance": 0.006292, "average": 0.964558, "min": 0.719046}, "location": {"width": 234, "top": 245, "height": 24, "left": 215}, "words": "95%CI为-0.84,-0.54)"}, {"probability": {"variance": 0, "average": 0.999728, "min": 0.998632}, "location": {"width": 296, "top": 306, "height": 29, "left": 212}, "words": "成人和青少年常年性变应性鼻炎"}, {"probability": {"variance": 0.002785, "average": 0.983751, "min": 0.6856}, "location": {"width": 774, "top": 338, "height": 30, "left": 252}, "words": "糠酸氟替卡松110μg,每日一次鼻内给药使每日 RTNSS得到显著的改善(LS平均差"}, {"probability": {"variance": 0.00524, "average": 0.981226, "min": 0.549704}, "location": {"width": 807, "top": 370, "height": 25, "left": 215}, "words": "0.706,P=0.005,95%CI为-1.20,-0.21)。每日一次给药后的鼻部症状改善可持续24"}, {"probability": {"variance": 1e-06, "average": 0.999643, "min": 0.994299}, "location": {"width": 707, "top": 401, "height": 26, "left": 214}, "words": "小时。与安慰剂相比较,患者感觉的整体治疗有效的分布情况也有显著的改善"}, {"probability": {"variance": 0.000734, "average": 0.987251, "min": 0.893668}, "location": {"width": 773, "top": 464, "height": 27, "left": 253}, "words": "在一项评估糠酸氟替卡松(每天一次鼻内喷雾110g)眼睛安全性的两年研究中,常"}, {"probability": {"variance": 0.01049, "average": 0.974147, "min": 0.375306}, "location": {"width": 810, "top": 496, "height": 27, "left": 214}, "words": "年变应性鼻炎的成年和青少年患者分别接受糠酸氟替卡松(n=367)或安慰剂(n181)治"}, {"probability": {"variance": 0.004593, "average": 0.972281, "min": 0.674148}, "location": {"width": 813, "top": 527, "height": 26, "left": 211}, "words": "疗。发现两个治疗组的主要结果后囊下混浊的增加时间(晶状体混浊分类系统第Ⅲ版"}, {"probability": {"variance": 0.004952, "average": 0.967954, "min": 0.657423}, "location": {"width": 799, "top": 559, "height": 26, "left": 227}, "words": "( LOCS III级)比基线增加0.3)]和眼内压(IOP)升高(比基线升高7mmHg)的时间不"}, {"probability": {"variance": 0.019523, "average": 0.939231, "min": 0.372894}, "location": {"width": 811, "top": 590, "height": 26, "left": 212}, "words": "具有统计学差异。与安慰剂组[4(2%)]比,糠酸氟替卡松110g剂组14(4)]中的"}, {"probability": {"variance": 0.004807, "average": 0.979551, "min": 0.575451}, "location": {"width": 813, "top": 620, "height": 26, "left": 213}, "words": "受试者出现了更多的后囊下混浊增加症状(比基线增加0.3),其中,糠酸氟替卡松组中有"}, {"probability": {"variance": 0.017803, "average": 0.935341, "min": 0.396127}, "location": {"width": 811, "top": 652, "height": 26, "left": 213}, "words": "十位受试者、安慰剂组中有两位受试为一过性状。糠酸氟替卡松10g剂量组出现了"}, {"probability": {"variance": 0.009092, "average": 0.961477, "min": 0.559318}, "location": {"width": 815, "top": 683, "height": 27, "left": 213}, "words": "更多的IOP升高症状(比基线升高7 mmhg):糠酸氟替卡松110每天一次剂量组中有7"}, {"probability": {"variance": 0.004272, "average": 0.979128, "min": 0.617147}, "location": {"width": 811, "top": 714, "height": 25, "left": 212}, "words": "例(2%),安慰剂组中有1例(<1%),其中,糠酸氟替卡松组中有六位受试者、安慰剂组"}, {"probability": {"variance": 0.006866, "average": 0.968338, "min": 0.593415}, "location": {"width": 811, "top": 744, "height": 28, "left": 212}, "words": "中有一位受试者为一过性症状。在第52和1014周,两个治疗维中95%受试者的每个眼睛"}, {"probability": {"variance": 0.008349, "average": 0.96853, "min": 0.579479}, "location": {"width": 811, "top": 777, "height": 26, "left": 213}, "words": "的后囊下混浊检测值在±0.1基线值范围内;在第104周,两个治疗组中≤1%受试者的斤"}, {"probability": {"variance": 0.01582, "average": 0.945824, "min": 0.499821}, "location": {"width": 806, "top": 808, "height": 25, "left": 213}, "words": "囊下混浊检测值比基线值增加了0.3,在第52和104周,大多数受试者(>95%)的IO"}, {"probability": {"variance": 0.00872, "average": 0.969276, "min": 0.472541}, "location": {"width": 814, "top": 839, "height": 27, "left": 212}, "words": "检测值在±5mmHg基线值范围内。后囊下混浊增加和IOP升高并没有导致出现白内障或"}, {"probability": {"variance": 0.009021, "average": 0.967852, "min": 0.682934}, "location": {"width": 210, "top": 871, "height": 26, "left": 213}, "words": "青光眼的任何不良事件"}, {"probability": {"variance": 0, "average": 0.999938, "min": 0.999891}, "location": {"width": 46, "top": 932, "height": 26, "left": 212}, "words": "儿童"}, {"probability": {"variance": 2e-06, "average": 0.999065, "min": 0.99235}, "location": {"width": 774, "top": 962, "height": 27, "left": 254}, "words": "根据对整个变应性鼻炎儿童人群疗效数据的评价确定了儿童给药剂量。在一项儿童季"}, {"probability": {"variance": 0.006722, "average": 0.9811, "min": 0.438896}, "location": {"width": 807, "top": 994, "height": 27, "left": 214}, "words": "节性变应性鼻炎试验中,在主要鼻部终点(每日 RTNSS LS平均差=0.616,P=0.025,95%C"}, {"probability": {"variance": 0.007914, "average": 0.975226, "min": 0.491556}, "location": {"width": 803, "top": 1023, "height": 30, "left": 213}, "words": "为1.15,-0.08)和所有次要鼻部终点方面,糠酸氟替卡松110ug鼻内给药2周均有效"}, {"probability": {"variance": 0.000267, "average": 0.995021, "min": 0.900463}, "location": {"width": 816, "top": 1056, "height": 28, "left": 211}, "words": "除流涕患者的回顾评分之外。在糠酸氟替卡松55μg与安慰剂之间,所有终点指标均没有"}, {"probability": {"variance": 1e-06, "average": 0.999149, "min": 0.997639}, "location": {"width": 190, "top": 1088, "height": 26, "left": 214}, "words": "观察到显著性的差异"}, {"probability": {"variance": 0.000518, "average": 0.993942, "min": 0.862531}, "location": {"width": 771, "top": 1150, "height": 27, "left": 256}, "words": "在一项常年性变应性鼻炎试验中,糠酸氟替卡松55μg鼻内给药对每日 TTNSS均有效"}, {"probability": {"variance": 0.009235, "average": 0.943738, "min": 0.610656}, "location": {"width": 797, "top": 1180, "height": 29, "left": 228}, "words": "(S平均差=0.754,P=0.003,95%CI为-1.24,-0.27)。虽然在100μg给药组中 RINSS"}, {"probability": {"variance": 0.003245, "average": 0.985311, "min": 0.603283}, "location": {"width": 812, "top": 1212, "height": 26, "left": 214}, "words": "有改善的趋势,但还未达到显著统计学意义(LS平均差=-0.452,P=0.073,95%CI为一"}, {"probability": {"variance": 0.003374, "average": 0.988441, "min": 0.6103}, "location": {"width": 815, "top": 1242, "height": 27, "left": 212}, "words": "124,-0.04)。对这项试验的6周、12周析因分析,以及另一项6周HPA轴安全性试验"}, {"probability": {"variance": 0.000847, "average": 0.990049, "min": 0.83917}, "location": {"width": 816, "top": 1274, "height": 27, "left": 213}, "words": "疗效数据的析因分析均显示,与安慰剂相比较,糠酸氟替卡松110μg鼻内喷雾给药对 TTNSS"}, {"probability": {"variance": 0.000179, "average": 0.995775, "min": 0.916389}, "location": {"width": 863, "top": 1303, "height": 34, "left": 213}, "words": "的改善具有显著统计学意义。一项安慰剂对照的糠酸氟替卡松110g,每日一次给药"}, {"probability": {"variance": 2e-06, "average": 0.998945, "min": 0.99362}, "location": {"width": 604, "top": 1337, "height": 26, "left": 305}, "words": "y试验结果显示,对儿童小腿生长速率短期没有临床相关性的影响"}, {"probability": {"variance": 0, "average": 0.790094, "min": 0.790094}, "location": {"width": 35, "top": 1325, "height": 37, "left": 944}, "words": "②"}, {"probability": {"variance": 0, "average": 0.985457, "min": 0.985457}, "location": {"width": 194, "top": 1351, "height": 58, "left": 871}, "words": "专"}, {"probability": {"variance": 0.001254, "average": 0.987396, "min": 0.854287}, "location": {"width": 774, "top": 1407, "height": 35, "left": 255}, "words": "在一项随机、双盲、平行组、多中心、安慰剂对照的一年临床生长研究中使用"}, {"probability": {"variance": 0.010271, "average": 0.964845, "min": 0.446811}, "location": {"width": 720, "top": 1445, "height": 27, "left": 287}, "words": "ty评估青春期前儿童(女孩为5~7.5岁,男孩为5~8.5岁)每天进行弊腔喷雾"}, {"probability": {"variance": 0.008557, "average": 0.972212, "min": 0.470085}, "location": {"width": 812, "top": 1478, "height": 26, "left": 214}, "words": "次110g糠酸氟替卡松对生长速度的影响作用,结果发现糠酸氟替卡松组儿童在52周治疗"}, {"probability": {"variance": 0.002678, "average": 0.978687, "min": 0.809963}, "location": {"width": 814, "top": 1509, "height": 25, "left": 215}, "words": "期内的平均生长速度(5.19cm/年)与安慰剂组(5.46cm/年)相比减慢,二者之间平均相"}, {"probability": {"variance": 0.02882, "average": 0.914081, "min": 0.387942}, "location": {"width": 380, "top": 1542, "height": 24, "left": 216}, "words": "差0.27cm/年[95%CI.0.48至-0.06]"}], "language": 3}